#1.2
13	225
CASRN	Name	Obesity, Morbid | CTD_CHEMICALS_DISEASES | 7.69e-05	Tox21_PPARd_BLA_antagonist_ratio | TOXCAST_ACTIVE | 1.57e-04	APR_HepG2_CellLoss_72h_dn | TOXCAST_ACTIVE | 2.68e-02	Developmental Toxicity-weight dec. rodent | LEADSCOPE_TOXICITY | 1.06e-03	Tooth Abnormalities | CTD_CHEMICALS_DISEASES | 4.89e-02	AR | CTD_CHEM2GENE_25 | 7.49e-03	Tox21 ARE activation assay, strong and weak actives by NIEHS calls, research only | MULTICASE_TOX_PREDICTION | 3.48e-04	KEGG:00510|N-Glycan biosynthesis | CTD_PATHWAY | 1.47e-02	Chronobiology Disorders | CTD_CHEMICALS_DISEASES | 2.93e-03	BSK_SAg_IL8_down | TOXCAST_ACTIVE | 2.45e-02	BSK_BE3C_TGFb1_down | TOXCAST_ACTIVE | 2.71e-02	Carcinoma, Lobular | CTD_CHEMICALS_DISEASES | 4.43e-02	ATG_PXR_TRANS_up | TOXCAST_ACTIVE | 1.08e-03	BSK_4H_uPAR_down | TOXCAST_ACTIVE | 1.25e-02	KEGG:01040|Biosynthesis of unsaturated fatty acids | CTD_PATHWAY | 4.68e-02	Uterine Neoplasms | CTD_CHEM2DISEASE | 3.09e-02	NVS_NR_hAR | TOXCAST_ACTIVE | 1.04e-03	Fatigue | CTD_CHEMICALS_DISEASES | 2.09e-02	estrogen receptor | MECH_LEVEL_3 | 1.31e-02	KEGG:00360|Phenylalanine metabolism | CTD_PATHWAY | 3.47e-02	KEGG:04330|Notch signaling pathway | CTD_PATHWAY | 3.54e-02	Human plasma protein binding, %bound | MULTICASE_TOX_PREDICTION | 8.73e-03	BSK_LPS_PGE2_down | TOXCAST_ACTIVE | 1.70e-02	BSK_3C_SRB_down | TOXCAST_ACTIVE | 3.68e-02	OT_ERa_EREGFP_0120 | TOXCAST_ACTIVE | 6.09e-04	Local lymph node assay, mouse, weak sensitizers (EC3 < 100%) | MULTICASE_TOX_PREDICTION | 1.61e-02	KEGG:03060|Protein export | CTD_PATHWAY | 1.32e-02	NVS_GPCR_hAdoRA2a | TOXCAST_ACTIVE | 3.20e-02	Urethral Stricture | CTD_CHEM2DISEASE | 4.59e-03	antagonism_ER/partial | HTS_ACTIVE | 3.69e-04	antagonism_AR/partial | HTS_ACTIVE | 9.79e-04	ATG_CRE_CIS_up | TOXCAST_ACTIVE | 2.61e-02	BSK_4H_MCP1_down | TOXCAST_ACTIVE | 1.96e-02	NVS_GPCR_rOpiate_NonSelective | TOXCAST_ACTIVE | 1.89e-03	KEGG:03015|mRNA surveillance pathway | CTD_PATHWAY | 3.09e-02	ESRRG | DRUGBANK_TARGETS | 6.64e-03	BSK_BE3C_MMP1_down | TOXCAST_ACTIVE | 1.09e-02	ATG_Xbp1_CIS_up | TOXCAST_ACTIVE | 4.95e-04	RCA fetal weight decrease, rodent | MULTICASE_TOX_PREDICTION | 8.37e-03	NVS_ADME_hCYP3A4 | TOXCAST_ACTIVE | 4.63e-02	Vitamin A Deficiency | CTD_CHEMICALS_DISEASES | 8.13e-03	NVS_NR_bER | TOXCAST_ACTIVE | 1.48e-08	OT_AR_ARSRC1_0960 | TOXCAST_ACTIVE | 1.04e-02	KEGG:00480|Glutathione metabolism | CTD_PATHWAY | 3.47e-02	BSK_SAg_Proliferation_down | TOXCAST_ACTIVE | 2.30e-02	Weight Gain | CTD_CHEMICALS_DISEASES | 1.61e-02	ACEA_T47D_80hr_Positive | TOXCAST_ACTIVE | 7.59e-04	NVS_GPCR_rOpiate_NonSelectiveNa | TOXCAST_ACTIVE | 1.54e-03	APR_HepG2_CellLoss_24h_dn | TOXCAST_ACTIVE | 2.99e-02	ATG_VDRE_CIS_up | TOXCAST_ACTIVE | 1.18e-03	VACTERL Association With Hydrocephalus | CTD_CHEMICALS_DISEASES | 1.86e-02	ATG_MRE_CIS_up | TOXCAST_ACTIVE | 3.01e-04	ATG_EGR_CIS_up | TOXCAST_ACTIVE | 3.91e-04	ATG_PPRE_CIS_up | TOXCAST_ACTIVE | 1.43e-02	NVS_GPCR_hOpiate_D1 | TOXCAST_ACTIVE | 1.62e-03	BSK_CASM3C_Proliferation_down | TOXCAST_ACTIVE | 8.33e-03	bond:COH_alcohol_generic | TOXPRINT_STRUCTURE | 9.99e-08	BSK_3C_IL8_down | TOXCAST_ACTIVE | 1.23e-02	Edema | CTD_CHEM2DISEASE | 4.45e-02	chain:aromaticAlkane_Ph-C1_acyclic_connect_noDblBd | TOXPRINT_STRUCTURE | 1.39e-04	Nervous System Malformations | CTD_CHEM2DISEASE | 3.09e-02	Reproductive Toxicity- C3H10T1-2 | LEADSCOPE_TOXICITY | 1.54e-02	ring:aromatic_benzene | TOXPRINT_STRUCTURE | 8.77e-04	ATG_GLI_CIS_up | TOXCAST_ACTIVE | 8.58e-03	BE0000132 | TOXINS_TARGETS | 7.62e-03	BE0000794 | TOXINS_TARGETS | 4.65e-03	NVS_GPCR_hDRD1 | TOXCAST_ACTIVE | 6.58e-03	NTCP substrates | MULTICASE_TOX_PREDICTION | 2.01e-02	NVS_NR_hGR | TOXCAST_ACTIVE | 1.31e-04	antagonism_AR/full/run1 | HTS_ACTIVE | 1.40e-04	bond:COH_alcohol_aromatic | TOXPRINT_STRUCTURE | 4.16e-13	KEGG:04141|Protein processing in endoplasmic reticulum | CTD_PATHWAY | 3.37e-02	NVS_NR_hER | TOXCAST_ACTIVE | 7.72e-09	ACEA_T47D_80hr_Negative | TOXCAST_ACTIVE | 5.52e-03	activation_Nrf2 | HTS_ACTIVE | 2.33e-02	NVS_TR_rVMAT2 | TOXCAST_ACTIVE | 1.76e-02	Weight Gain | CTD_CHEM2DISEASE | 6.99e-05	BSK_3C_Vis_down | TOXCAST_ACTIVE | 3.46e-03	Microsatellite Instability | CTD_CHEMICALS_DISEASES | 8.20e-03	Uveal melanoma | CTD_CHEMICALS_DISEASES | 2.50e-02	KEGG:04130|SNARE interactions in vesicular transport | CTD_PATHWAY | 1.40e-02	NVS_IC_rCaBTZCHL | TOXCAST_ACTIVE | 2.48e-02	KEGG:03008|Ribosome biogenesis in eukaryotes | CTD_PATHWAY | 2.86e-02	Tox21_p53_BLA_p5_ratio | TOXCAST_ACTIVE | 1.55e-03	estrogen receptor agonist | MECH_LEVEL_2 | 1.24e-02	BSK_SAg_CD40_down | TOXCAST_ACTIVE | 4.06e-02	BSK_4H_VCAM1_down | TOXCAST_ACTIVE | 2.01e-02	antagonism_AR/full/run2 | HTS_ACTIVE | 2.09e-03	KEGG:04114|Oocyte meiosis | CTD_PATHWAY | 1.76e-03	BSK_hDFCGF_VCAM1_down | TOXCAST_ACTIVE | 2.42e-02	RCA survival pre-implantation, rodent | MULTICASE_TOX_PREDICTION | 3.66e-02	chain:aromaticAlkane_Ph-C1_acyclic_generic | TOXPRINT_STRUCTURE | 3.02e-03	Developmental Toxicity-pre impl. loss rat | LEADSCOPE_TOXICITY | 3.17e-02	Wilms Tumor | CTD_CHEMICALS_DISEASES | 2.71e-04	BSK_3C_Proliferation_down | TOXCAST_ACTIVE | 2.03e-02	chain:aromaticAlkane_Ar-C-Ar | TOXPRINT_STRUCTURE | 8.41e-08	BSK_CASM3C_MCSF_down | TOXCAST_ACTIVE | 3.47e-02	KEGG:00520|Amino sugar and nucleotide sugar metabolism | CTD_PATHWAY | 3.32e-02	MRP2 substrates | MULTICASE_TOX_PREDICTION | 2.31e-04	NVS_ADME_hCYP19A1 | TOXCAST_ACTIVE | 3.89e-02	NVS_TR_gDAT | TOXCAST_ACTIVE | 9.67e-04	BE0000956 | TOXINS_TARGETS | 1.96e-02	APR_HepG2_OxidativeStress_24h_up | TOXCAST_ACTIVE | 1.29e-02	ATG_SREBP_CIS_up | TOXCAST_ACTIVE | 9.27e-03	NVS_GPCR_hAdrb1 | TOXCAST_ACTIVE | 2.39e-02	MRP1 substrates | MULTICASE_TOX_PREDICTION | 1.21e-05	Hydrocarbons, Aromatic | MESH | 7.95e-06	NVS_GPCR_g5HT4 | TOXCAST_ACTIVE | 2.03e-04	BSK_LPS_MCSF_down | TOXCAST_ACTIVE | 2.78e-02	Uterine Diseases | CTD_CHEM2DISEASE | 1.83e-02	NVS_GPCR_hOpiate_mu | TOXCAST_ACTIVE | 8.71e-04	BSK_hDFCGF_IP10_down | TOXCAST_ACTIVE | 2.42e-02	Developmental Toxicity-retardation rat | LEADSCOPE_TOXICITY | 3.17e-05	BSK_LPS_VCAM1_down | TOXCAST_ACTIVE | 4.79e-03	KEGG:04710|Circadian rhythm - mammal | CTD_PATHWAY | 3.24e-02	OT_ER_ERaERb_1440 | TOXCAST_ACTIVE | 6.39e-05	cytotoxicity_Nrf2/activation | HTS_ACTIVE | 4.80e-02	NVS_NR_hPPARa | TOXCAST_ACTIVE | 2.75e-04	Bone Diseases, Developmental | CTD_CHEMICALS_DISEASES | 5.00e-02	cytotoxicity_H2AX/activation | HTS_ACTIVE | 1.65e-02	bond:COH_alcohol_aromatic_phenol | TOXPRINT_STRUCTURE | 2.59e-13	cytotoxicity_AR/antagonism/partial | HTS_ACTIVE | 2.80e-02	BSK_4H_SRB_down | TOXCAST_ACTIVE | 1.67e-02	Estrogens | PHARMACTIONLIST | 8.46e-03	KEGG:03018|RNA degradation | CTD_PATHWAY | 3.54e-02	inhibition_MMP | HTS_ACTIVE | 1.78e-05	BSK_SAg_CD69_down | TOXCAST_ACTIVE | 2.45e-02	BSK_hDFCGF_Proliferation_down | TOXCAST_ACTIVE | 2.76e-02	ATG_PPARg_TRANS_up | TOXCAST_ACTIVE | 1.07e-02	Tox21 ARE activation assay, only strong actives by NIEHS calls, research only | MULTICASE_TOX_PREDICTION | 3.19e-04	BSK_LPS_SRB_down | TOXCAST_ACTIVE | 1.90e-02	Neurotoxicityy-pup behavior rodent | LEADSCOPE_TOXICITY | 2.26e-02	ATG_CMV_CIS_up | TOXCAST_ACTIVE | 1.11e-02	chain:alkaneBranch_neopentyl_C5 | TOXPRINT_STRUCTURE | 3.46e-06	Tox21_FXR_BLA_antagonist_ratio | TOXCAST_ACTIVE | 7.67e-03	KEGG:03440|Homologous recombination | CTD_PATHWAY | 3.09e-02	Genetic Toxicity -chrom. ab. | LEADSCOPE_TOXICITY | 1.14e-03	KEGG:00052|Galactose metabolism | CTD_PATHWAY | 4.38e-02	Prostatic Diseases | CTD_CHEM2DISEASE | 1.10e-02	NVS_NR_rAR | TOXCAST_ACTIVE | 5.83e-06	Tox21_PPARg_BLA_antagonist_ratio | TOXCAST_ACTIVE | 2.23e-05	OT_ER_ERaERa_1440 | TOXCAST_ACTIVE | 1.58e-06	NVS_LGIC_rGluNMDA_Agonist | TOXCAST_ACTIVE | 2.19e-03	NVS_NR_hPR | TOXCAST_ACTIVE | 3.98e-04	BSK_3C_MCP1_down | TOXCAST_ACTIVE | 1.62e-02	OT_FXR_FXRSRC1_0480 | TOXCAST_ACTIVE | 9.53e-04	NVS_NR_cAR | TOXCAST_ACTIVE | 9.21e-04	NVS_ADME_hCYP2B6 | TOXCAST_ACTIVE | 9.32e-03	Scleroatonic muscular dystrophy | CTD_CHEMICALS_DISEASES | 2.44e-02	Tox21_ERa_BLA_Antagonist_ratio | TOXCAST_ACTIVE | 7.07e-04	Tox21_MitochondrialToxicity_ratio | TOXCAST_ACTIVE | 1.22e-04	BSK_hDFCGF_CollagenIII_down | TOXCAST_ACTIVE | 3.64e-02	OT_ERa_EREGFP_0480 | TOXCAST_ACTIVE | 2.40e-04	BE0000557 | TOXINS_TARGETS | 1.22e-03	Substance-Related Disorders | CTD_CHEMICALS_DISEASES | 3.59e-02	NVS_GPCR_h5HT6 | TOXCAST_ACTIVE | 1.99e-03	Tox21_p53_BLA_p1_ratio | TOXCAST_ACTIVE | 4.60e-02	ATG_TA_CIS_up | TOXCAST_ACTIVE | 1.97e-03	Hypertrophy | CTD_CHEM2DISEASE | 2.29e-03	Tox21_ERa_BLA_Agonist_ratio | TOXCAST_ACTIVE | 4.87e-05	ATG_FXR_TRANS_up | TOXCAST_ACTIVE | 2.74e-02	Tox21_TR_LUC_GH3_Antagonist | TOXCAST_ACTIVE | 5.26e-03	NVS_GPCR_h5HT7 | TOXCAST_ACTIVE | 1.04e-02	NVS_GPCR_hAdoRA1 | TOXCAST_ACTIVE | 3.94e-03	OT_ER_ERbERb_1440 | TOXCAST_ACTIVE | 5.94e-04	antagonism_PPARg | HTS_ACTIVE | 1.15e-05	NVS_NR_hPPARg | TOXCAST_ACTIVE | 3.99e-03	Tox21_AR_LUC_MDAKB2_Antagonist | TOXCAST_ACTIVE | 2.09e-03	ATG_Sox_CIS_up | TOXCAST_ACTIVE | 1.36e-02	NVS_IC_rNaCh_site2 | TOXCAST_ACTIVE | 6.25e-04	ATG_BRE_CIS_up | TOXCAST_ACTIVE | 2.24e-02	KEGG:00630|Glyoxylate and dicarboxylate metabolism | CTD_PATHWAY | 3.77e-02	Branchio-Oto-Renal Syndrome | CTD_CHEMICALS_DISEASES | 4.68e-05	ATG_HSE_CIS_up | TOXCAST_ACTIVE | 8.42e-05	Tox21_ERa_LUC_BG1_Agonist | TOXCAST_ACTIVE | 3.83e-04	ATG_Oct_MLP_CIS_up | TOXCAST_ACTIVE | 1.78e-03	ATG_ERE_CIS_up | TOXCAST_ACTIVE | 2.12e-03	Pleural Diseases | CTD_CHEMICALS_DISEASES | 4.07e-02	ARE activation in keratinocytes at 1mM | MULTICASE_TOX_PREDICTION | 3.00e-05	NVS_NR_bPR | TOXCAST_ACTIVE | 2.75e-04	OT_ER_ERaERa_0480 | TOXCAST_ACTIVE | 6.08e-06	Tox21_AR_BLA_Antagonist_ratio | TOXCAST_ACTIVE | 1.86e-03	KEGG:03022|Basal transcription factors | CTD_PATHWAY | 1.63e-02	Feminization | CTD_CHEM2DISEASE | 9.16e-03	OT_ER_ERaERb_0480 | TOXCAST_ACTIVE | 1.01e-04	Infertility, Female | CTD_CHEM2DISEASE | 3.18e-02	Benzene Derivatives | MESH | 7.96e-07	ATG_Pax6_CIS_up | TOXCAST_ACTIVE | 9.59e-06	OCT1 substrates | MULTICASE_TOX_PREDICTION | 5.15e-07	Myoclonic Epilepsies, Progressive | CTD_CHEMICALS_DISEASES | 3.47e-02	Reproductive Toxicity -repro mouse female | LEADSCOPE_TOXICITY | 1.67e-05	NVS_GPCR_gLTB4 | TOXCAST_ACTIVE | 2.31e-02	NVS_ADME_hCYP2C19 | TOXCAST_ACTIVE | 3.60e-02	chain:aromaticAlkane_Ph-C1-Ph | TOXPRINT_STRUCTURE | 2.04e-08	antagonism_GR | HTS_ACTIVE | 6.38e-04	ATG_ERa_TRANS_up | TOXCAST_ACTIVE | 2.93e-05	agonism_ER/full | HTS_ACTIVE | 6.09e-06	Developmental Toxicity-weight dec. rat | LEADSCOPE_TOXICITY | 1.68e-03	BSK_3C_uPAR_down | TOXCAST_ACTIVE | 2.18e-02	KEGG:00565|Ether lipid metabolism | CTD_PATHWAY | 2.63e-02	Tox21_p53_BLA_p4_ratio | TOXCAST_ACTIVE | 2.86e-03	NVS_MP_rPBR | TOXCAST_ACTIVE | 1.17e-02	KEGG:03020|RNA polymerase | CTD_PATHWAY | 1.01e-02	Benzhydryl Compounds | MESH | 3.72e-05	NVS_GPCR_p5HT2C | TOXCAST_ACTIVE | 2.08e-03	BSK_SAg_MCP1_down | TOXCAST_ACTIVE | 1.96e-02	NVS_NR_hFXR_Antagonist | TOXCAST_ACTIVE | 3.10e-02	NVS_TR_hDAT | TOXCAST_ACTIVE | 7.15e-03	Urogenital Abnormalities | CTD_CHEM2DISEASE | 1.64e-02	Reproductive Toxicity -repro rodent female | LEADSCOPE_TOXICITY | 2.57e-04	NVS_TR_hNET | TOXCAST_ACTIVE | 3.15e-03	Meningioma | CTD_CHEMICALS_DISEASES | 1.58e-02	NVS_NR_mERa | TOXCAST_ACTIVE | 4.07e-07	OT_ER_ERbERb_0480 | TOXCAST_ACTIVE | 1.23e-03	APR_HepG2_OxidativeStress_72h_up | TOXCAST_ACTIVE | 1.46e-02	Hydrocarbons | MESH | 1.90e-04	agonism_ER/partial | HTS_ACTIVE | 7.28e-10	NVS_ADME_hCYP2C9 | TOXCAST_ACTIVE | 4.69e-04	KEGG:00600|Sphingolipid metabolism | CTD_PATHWAY | 2.70e-02	KEGG:00970|Aminoacyl-tRNA biosynthesis | CTD_PATHWAY | 1.55e-02	Tox21_GR_BLA_Antagonist_ratio | TOXCAST_ACTIVE | 9.20e-06	Hydrocarbons, Cyclic | MESH | 2.07e-05	Phenols | MESH | 3.42e-05	KEGG:00030|Pentose phosphate pathway | CTD_PATHWAY | 4.61e-02	KEGG:04962|Vasopressin-regulated water reabsorption | CTD_PATHWAY | 3.85e-02
77-40-7		0	1	1	1	0	0	1	0	0	1	0	0	1	1	0	0	1	0	0	0	0	1	1	1	1	1	0	0	0	1	1	0	1	1	0	0	0	1	0	0	0	1	0	0	1	0	1	1	1	1	0	1	1	0	1	1	1	1	0	1	0	1	1	0	0	0	1	0	1	1	1	0	1	1	1	1	0	1	0	0	0	0	0	1	0	1	1	1	0	1	0	1	1	0	1	1	1	0	1	0	1	0	1	1	0	1	1	1	1	0	1	1	1	1	0	1	0	0	0	0	1	1	1	0	0	1	1	1	1	1	1	1	0	1	0	0	1	0	0	1	1	1	1	1	1	1	1	1	0	1	1	1	1	0	0	1	0	0	0	0	0	1	1	1	1	1	0	1	0	1	0	0	0	0	1	1	1	0	1	1	1	1	0	0	1	0	1	1	1	0	1	1	1	1	1	1	1	1	1	0	1	0	0	1	1	1	0	1	0	1	1	0	1	1	1	1	1	1	0	0	1	1	1	0	0
41481-66-7		0	1	1	0	0	0	1	0	0	1	1	0	1	1	0	0	1	0	0	0	0	1	1	1	0	1	0	1	0	1	1	1	1	1	0	0	1	1	0	1	0	1	0	0	1	0	0	1	1	1	0	1	1	1	1	1	1	1	0	1	0	0	1	0	0	0	1	1	1	1	1	0	1	1	0	0	0	1	0	0	0	1	0	1	0	1	1	1	0	1	0	1	0	0	1	0	1	0	1	0	1	0	1	1	1	1	0	1	1	0	1	1	0	1	0	0	0	1	0	1	1	0	1	0	0	1	1	1	1	0	1	0	1	0	1	0	0	0	0	1	1	0	0	0	1	0	1	1	0	1	1	1	0	0	0	1	0	1	0	0	0	1	1	1	0	1	1	1	0	1	1	0	0	1	0	1	1	0	1	1	0	1	0	0	0	0	0	1	1	0	0	0	1	0	0	1	0	0	1	0	1	0	0	0	1	1	1	1	0	0	1	0	1	0	1	0	0	1	0	0	1	0	0	0	0
80-05-7		1	1	1	1	1	0	1	1	0	0	0	0	1	0	1	1	1	1	1	1	1	1	1	0	1	1	1	0	1	1	1	1	1	1	1	1	0	1	1	0	0	1	1	1	1	0	1	1	1	1	0	1	1	1	1	1	1	0	1	1	1	1	1	0	0	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	1	1	1	1	1	1	0	1	1	1	1	1	0	1	0	0	1	0	1	1	1	1	1	1	0	1	1	1	1	1	1	1	0	1	0	0	1	0	0	1	1	1	1	1	1	1	0	1	1	1	0	1	1	1	1	1	1	1	1	1	0	1	1	1	0	1	1	1	1	0	1	1	0	1	1	1	1	1	1	1	1	1	0	1	0	1	1	1	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	1	1	1	1	1	0	1	0	1	1	1	1	0	1	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1
1478-61-1		0	1	1	1	0	0	1	0	0	1	1	0	1	1	0	0	1	0	0	0	0	1	1	1	1	1	0	1	0	1	1	1	1	0	0	0	1	1	0	1	0	1	1	0	1	0	1	1	0	1	0	1	0	1	1	1	1	1	0	1	0	1	1	0	0	0	1	0	1	1	1	0	1	1	1	1	0	1	0	0	0	0	0	1	0	1	1	1	0	1	0	1	1	0	1	1	0	0	1	1	1	0	0	0	1	1	1	1	1	0	1	1	1	1	0	1	0	1	0	1	1	1	1	0	0	1	1	1	0	1	1	1	1	1	1	0	1	0	0	1	1	1	1	1	1	1	1	1	0	1	1	1	1	0	0	1	1	0	0	1	0	1	1	1	1	1	1	1	0	1	1	0	0	1	1	1	1	0	1	1	1	1	0	0	1	0	1	1	1	0	1	1	1	1	1	1	1	1	1	0	1	1	0	0	1	1	1	1	0	0	1	0	1	1	0	1	1	1	0	0	1	1	1	0	0
843-55-0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
79-95-8		0	0	0	0	1	1	1	0	1	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	0	0	0	1	0	0	1	1	1	1	0	0	0	1	0	0	1	0	1	1	1	1	1	0	1	1	0	1	0	1	1	1	0	1	0	1	0	0	0	0	1	0	0	0	0	1	0	1	1	0	1	0	1	0	0	1	0	0	1	0	0	0	1	1	0	0	0	0	0	1	0	0	1	1	1	1	0	1	1	0	0	0	1	0	0	1	1	0	0	1	1	1	0	1	0	0	1	1	1	0	0	0	1	0	0	1	1	1	0	1	1	0	0	1	0	0	1	1	1	0	0	0	1	1	0	1	0	0	0	1	1	1	0	1	0	1	0	1	0	0	0	1	0	1	1	1	0	1	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	0	0	1	1	0	0	0	1	1	1	0	0
620-92-8		0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	1	0	0	1	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	1	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	0	1	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0
79-94-7		1	1	1	0	0	1	1	0	1	1	1	0	1	1	0	0	0	0	0	0	0	1	1	1	0	1	0	0	0	0	0	1	1	0	0	0	1	1	1	0	1	0	1	1	1	1	0	0	1	1	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	0	1	1	1	1	1	1	1	1	0	1	1	0	0	0	0	0	1	0	1	1	0	1	1	1	1	0	1	1	1	1	0	1	0	0	1	1	1	0	1	1	0	1	0	0	1	1	1	0	0	1	1	0	1	1	1	1	0	0	1	1	1	1	1	1	1	1	1	1	0	0	0	0	1	1	0	0	1	1	1	0	0	0	1	1	1	0	1	0	0	1	1	0	0	0	1	0	0	0	1	1	1	1	0	0	0	1	1	0	1	0	1	1	0	0	0	0	0	0	0	1	1	1	0	1	0	1	1	0	1	0	0	1	0	1	0	0	0	0	1	0	0	0	1	0	1	1	0	1	1	1	1	0	0	1	1	0	0	0
5613-46-7		0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	1	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	1	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
80-09-1		1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	0	0	0	1	0	1	0	0	0	0	0	1	0	1	0	1	1	1	0	1	1	0	0	1	0	1	0	1	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	1	1	0	0
57-63-6		1	0	1	1	0	0	1	1	0	1	1	1	1	1	1	1	1	0	1	1	1	1	0	1	1	1	1	1	1	0	1	1	0	1	1	0	1	1	1	1	0	1	1	1	1	1	1	0	1	1	0	1	1	0	0	1	1	1	1	0	0	1	1	1	1	1	0	1	1	1	1	1	1	0	0	0	1	1	1	1	1	1	1	1	1	0	0	1	1	0	1	0	1	0	1	0	1	1	1	0	1	1	1	1	0	1	0	1	1	0	1	0	1	1	1	1	0	0	1	1	1	1	1	1	1	1	0	1	0	1	1	1	1	1	1	1	0	1	1	1	0	1	0	1	1	1	1	0	1	0	1	0	1	1	0	0	1	1	1	1	0	1	0	0	1	0	0	1	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	0	1	1	1	1	0	1	0	1	1	1	1	1	1	1	1	1	0	0	1	0	1	1	1	1	1	1	1	1	0	1	1	1	1	1	0	0	1	1
79-97-0		0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	1	0	0	0	0	1	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	1	0	0	1	1	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
94-18-8		0	1	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1	1	0	0	1	0	1	1	1	0	0	1	0	0	1	0	0	1	1	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	0	1	0	1	1	0	0	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	1	0	0	1	0	0	1	0	0	1	0	0	0	0	0	1	1	0	0	0	1	1	0	0	1	1	0	0	0	1	0	0	1	1	1	1	0	0	0	1	0	0	0	1	0	1	0	0	1	1	1	1	0	1	0	1	1	0	0	1	0	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	1	1	0	1	1	0	0	0	0	1	1	0	0
